Pra-Ornsuda Sukrakanchana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pra-Ornsuda Sukrakanchana has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
- Paul K. Drain
Department of Global Health, Schools of Medicine and Public Health, University of Washington, Seattle, USA
2 shared publications - Wasna Sirirungsi
Faculty of Associated Medical Sciences, Chiang Mai University
2 shared publications - A. Sarah Walker
Nuffield Department of Medicine, University of Oxford
1 shared publication - Adrie Bekker
Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University
1 shared publication - Aislinn Cook
Antibiotic Policy Group, Institute for Infection and Immunity, City St. George’s, University of London, London SW17 0RE, UK
1 shared publication - Alessandra Nardone
Fondazione Penta ETS, Padova, Italy
1 shared publication
Latest Publications
- Open Access
- 12 December 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (1)
Oral Fluid Concentrations of Tenofovir and Emtricitabine for Monitoring HIV Antiretroviral Adherence: Findings From a Randomized Trial with Directly Observed Therapy (TARGET Study)
Background: Early identification of non-adherence to daily antiretroviral therapies may facilitate targeted transition to long-acting HIV regimens for individuals most likely to benefit. This study evaluated the feasibility of detecting emtricitabine (FTC) and tenofovir (TFV) in oral fluids to monitor daily oral pre-exposure prophylaxis (PrEP) adherence. Methods: We collected 241 oral fluids from 22 HIV-negative adults randomized to 2, 4, or 7 doses/week of oral PrEP with FTC/TDF for directly observed therapy. Generalized Estimating Equations were used to examine the associations between FTC/TFV detectability and three dimensions of PrEP adherence: dosing recency, cumulative dosing time, and dosing frequency. We also assessed the diagnostic accuracy of FTC levels in oral fluids for predicting daily oral PrEP non-adherence (time since the last dose >24 hours). Results: Among 165 oral fluids with a time since the last dose within 48 hours, 9.0% had detectable TFV, and 53.3% had detectable FTC. Compared with oral fluids collected within 24 hours since the last dose, those collected between 24 and 48 hours since the last dose had significantly lower odds of having detectable FTC (odds ratio: 0.21, 95% confidence interval [CI]: 0.11–0.38). An FTC threshold of <7.5 ng/mL achieved a sensitivity of 90% (95% CI: 84%–94%) and a specificity of 65% (95% CI: 57%–74%) for identifying recent PrEP non-adherence. Conclusions: FTC can be detected in oral fluids and may be a promising pharmacologic marker for identifying recent PrEP non-adherence as early as one dose missed. TFV had lower concentrations in oral fluids, and is not suitable for adherence monitoring. Clinical Trials Registration. NCT0301260.
- 12 December 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (1)
Open AccessOral Fluid Concentrations of Tenofovir and Emtricitabine for Monitoring HIV Antiretroviral Adherence: Findings From a Randomized Trial with Directly Observed Therapy (TARGET Study)
Background: Early identification of non-adherence to daily antiretroviral therapies may facilitate targeted transition to long-acting HIV regimens for individuals most likely to benefit. This study evaluated the feasibility of detecting emtricitabine (FTC) and tenofovir (TFV) in oral fluids to monitor daily oral pre-exposure prophylaxis (PrEP) adherence. Methods: We collected 241 oral fluids from 22 HIV-negative adults randomized to 2, 4, or 7 doses/week of oral PrEP with FTC/TDF for directly observed therapy. Generalized Estimating Equations were used to examine the associations between FTC/TFV detectability and three dimensions of PrEP adherence: dosing recency, cumulative dosing time, and dosing frequency. We also assessed the diagnostic accuracy of FTC levels in oral fluids for predicting daily oral PrEP non-adherence (time since the last dose >24 hours). Results: Among 165 oral fluids with a time since the last dose within 48 hours, 9.0% had detectable TFV, and 53.3% had detectable FTC. Compared with oral fluids collected within 24 hours since the last dose, those collected between 24 and 48 hours since the last dose had significantly lower odds of having detectable FTC (odds ratio: 0.21, 95% confidence interval [CI]: 0.11–0.38). An FTC threshold of <7.5 ng/mL achieved a sensitivity of 90% (95% CI: 84%–94%) and a specificity of 65% (95% CI: 57%–74%) for identifying recent PrEP non-adherence. Conclusions: FTC can be detected in oral fluids and may be a promising pharmacologic marker for identifying recent PrEP non-adherence as early as one dose missed. TFV had lower concentrations in oral fluids, and is not suitable for adherence monitoring. Clinical Trials Registration. NCT0301260.
- Open Access
- 15 July 2024
- Published by MDPI AG in Preprints.org
Stigma and Discrimination among Adolescents Living with Perinatal HIV in Thailand: Reports from Their Caregivers
In Thailand, thousands of children living with perinatal HIV have been exposed to HIV-related stigma/discrimination but its frequency and expressions have been little studied. Our objective was to assess stigma/discrimination prevalence, associated risks factors and its expressions among adolescents. All caregivers of adolescents aged 12-19 years living with perinatal HIV and receiving antiretrovirals in 20 hospitals throughout Thailand were invited to complete a face-to-face questionnaire on their adolescent’s life and medical history. Of the 572 adolescents living in family settings, 464 had their HIV-status known in the community. The overall stigma/discrimination prevalence was 46%. Factors associated included living in the north-east region (OR: 2.80, 95%CI: 1.19-4.96), having a low intellectual ability (OR:2.68, 95%CI: 1.45-5.16), a lower Body Mass Index (BMI) (OR BMI > 18.5: 0.61, 95%CI: 0.37-0.98), conflicts with caregivers (OR: 1.86, 95%CI: 1.26-2.76) and caregivers being members of a support group (OR: 2.34, 95%CI: 1.58-3.48). Expressions of stigma/discrimination included bullying, social isolation, behavioral discrimination and public disclosure. The prevalence of stigma/discrimination among adolescents living with perinatal HIV is high. Despite existing policies, stigma eradication remains necessary to normalize their life as they grow into adulthood.
- 15 July 2024
- Published by MDPI AG in Preprints.org
Open AccessStigma and Discrimination among Adolescents Living with Perinatal HIV in Thailand: Reports from Their Caregivers
In Thailand, thousands of children living with perinatal HIV have been exposed to HIV-related stigma/discrimination but its frequency and expressions have been little studied. Our objective was to assess stigma/discrimination prevalence, associated risks factors and its expressions among adolescents. All caregivers of adolescents aged 12-19 years living with perinatal HIV and receiving antiretrovirals in 20 hospitals throughout Thailand were invited to complete a face-to-face questionnaire on their adolescent’s life and medical history. Of the 572 adolescents living in family settings, 464 had their HIV-status known in the community. The overall stigma/discrimination prevalence was 46%. Factors associated included living in the north-east region (OR: 2.80, 95%CI: 1.19-4.96), having a low intellectual ability (OR:2.68, 95%CI: 1.45-5.16), a lower Body Mass Index (BMI) (OR BMI > 18.5: 0.61, 95%CI: 0.37-0.98), conflicts with caregivers (OR: 1.86, 95%CI: 1.26-2.76) and caregivers being members of a support group (OR: 2.34, 95%CI: 1.58-3.48). Expressions of stigma/discrimination included bullying, social isolation, behavioral discrimination and public disclosure. The prevalence of stigma/discrimination among adolescents living with perinatal HIV is high. Despite existing policies, stigma eradication remains necessary to normalize their life as they grow into adulthood.
- Open Access
- 30 March 2024
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 143, 107021
Molnupiravir versus favipiravir in at-risk outpatients with COVID-19: A randomized controlled trial in Thailand
- 30 March 2024
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 143, 107021
Open AccessMolnupiravir versus favipiravir in at-risk outpatients with COVID-19: A randomized controlled trial in Thailand
- Open Access
- 17 May 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (5) , 923
Challenges in the Implementation of the NeoOBS Study, a Global Pragmatic Observational Cohort Study, to Investigate the Aetiology and Management of Neonatal Sepsis in the Hospital Setting
Neonatal sepsis is a significant cause of mortality and morbidity in low- and middle-income countries. To deliver high-quality data studies and inform future trials, it is crucial to understand the challenges encountered when managing global multi-centre research studies and to identify solutions that can feasibly be implemented in these settings. This paper provides an overview of the complexities faced by diverse research teams in different countries and regions, together with actions implemented to achieve pragmatic study management of a large multi-centre observational study of neonatal sepsis. We discuss specific considerations for enrolling sites with different approval processes and varied research experience, structures, and training. Implementing a flexible recruitment strategy and providing ongoing training were necessary to overcome these challenges. We emphasize the attention that must be given to designing the database and monitoring plans. Extensive data collection tools, complex databases, tight timelines, and stringent monitoring arrangements can be problematic and might put the study at risk. Finally, we discuss the complexities added when collecting and shipping isolates and the importance of having a robust central management team and interdisciplinary collaborators able to adapt easily and make swift decisions to deliver the study on time and to target. With pragmatic approaches, appropriate training, and good communication, these challenges can be overcome to deliver high-quality data from a complex study in challenging settings through a collaborative research network.
- 17 May 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (5) , 923
Open AccessChallenges in the Implementation of the NeoOBS Study, a Global Pragmatic Observational Cohort Study, to Investigate the Aetiology and Management of Neonatal Sepsis in the Hospital Setting
Neonatal sepsis is a significant cause of mortality and morbidity in low- and middle-income countries. To deliver high-quality data studies and inform future trials, it is crucial to understand the challenges encountered when managing global multi-centre research studies and to identify solutions that can feasibly be implemented in these settings. This paper provides an overview of the complexities faced by diverse research teams in different countries and regions, together with actions implemented to achieve pragmatic study management of a large multi-centre observational study of neonatal sepsis. We discuss specific considerations for enrolling sites with different approval processes and varied research experience, structures, and training. Implementing a flexible recruitment strategy and providing ongoing training were necessary to overcome these challenges. We emphasize the attention that must be given to designing the database and monitoring plans. Extensive data collection tools, complex databases, tight timelines, and stringent monitoring arrangements can be problematic and might put the study at risk. Finally, we discuss the complexities added when collecting and shipping isolates and the importance of having a robust central management team and interdisciplinary collaborators able to adapt easily and make swift decisions to deliver the study on time and to target. With pragmatic approaches, appropriate training, and good communication, these challenges can be overcome to deliver high-quality data from a complex study in challenging settings through a collaborative research network.
- Open Access
- 14 July 2017
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 17 (1) , 496
A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study
Tenofovir disoproxil fumarate (TDF) is key component of pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART) for HIV, but existing tools to monitor drug adherence are often inaccurate. Detection of tenofovir (TFV) in accessible biological samples, such as fingerprick blood, urine or oral fluid samples could be a novel objective measure of recent TDF adherence. To measure TFV concentrations associated with different levels of TDF adherence, we designed a randomized clinical trial to assess the blood, urine and oral fluid concentrations of TFV in adults with perfect, moderate and low drug adherence. A randomized, open-label, clinical pharmacokinetic study of tenofovir in healthy adult volunteers without HIV or Hepatitis B infection in Thailand. Consenting, eligible participants are randomized (1:1:1) among three groups to receive a controlled number of TDF (300 mg) doses in a combination pill with emtricitabine (FTC, 200 mg) for six weeks. Participants in Group 1 receive a single TDF/FTC tablet once daily (Perfect adherence); Group 2 receive a single TDF/FTC tablet 4 times/week (Moderate adherence); and Group 3 receive a single TDF/FTC tablet 2 times/week (Low adherence). Blood, plasma, urine and oral fluid samples are collected for drug measurement during three study phases: (i) initial 6-week treatment phase; (ii) intensive 24-h blood sampling phase after 6 weeks; (iii) 4-week washout phase. Thirty adults with evaluable pharmacokinetic samples (10 per group) will be enrolled [based on ensuring 25% precision in pharmacokinetic parameter estimates]. Pre-dose drug concentrations during the treatment phase will be descriptive and comparisons between groups performed using a Kruskal-Wallis test. A non-compartmental pharmacokinetic analysis will be performed on the intensive sampling data at Week 7 and the time course of TFV washout in the difference biological matrices will be reported based on the detected concentrations following drug cessation. The results of this randomized trial will define the target concentration thresholds of TFV in blood, urine and oral fluid that can distinguish between different levels of TDF adherence. Such adherence ‘benchmarks’ can be applied to real-time drug testing and novel point-of-care tests to identify individuals with poor PrEP or ART adherence. ClinicalTrials.gov Identifier NCT03012607 .
- 14 July 2017
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 17 (1) , 496
Open AccessA randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study
Tenofovir disoproxil fumarate (TDF) is key component of pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART) for HIV, but existing tools to monitor drug adherence are often inaccurate. Detection of tenofovir (TFV) in accessible biological samples, such as fingerprick blood, urine or oral fluid samples could be a novel objective measure of recent TDF adherence. To measure TFV concentrations associated with different levels of TDF adherence, we designed a randomized clinical trial to assess the blood, urine and oral fluid concentrations of TFV in adults with perfect, moderate and low drug adherence. A randomized, open-label, clinical pharmacokinetic study of tenofovir in healthy adult volunteers without HIV or Hepatitis B infection in Thailand. Consenting, eligible participants are randomized (1:1:1) among three groups to receive a controlled number of TDF (300 mg) doses in a combination pill with emtricitabine (FTC, 200 mg) for six weeks. Participants in Group 1 receive a single TDF/FTC tablet once daily (Perfect adherence); Group 2 receive a single TDF/FTC tablet 4 times/week (Moderate adherence); and Group 3 receive a single TDF/FTC tablet 2 times/week (Low adherence). Blood, plasma, urine and oral fluid samples are collected for drug measurement during three study phases: (i) initial 6-week treatment phase; (ii) intensive 24-h blood sampling phase after 6 weeks; (iii) 4-week washout phase. Thirty adults with evaluable pharmacokinetic samples (10 per group) will be enrolled [based on ensuring 25% precision in pharmacokinetic parameter estimates]. Pre-dose drug concentrations during the treatment phase will be descriptive and comparisons between groups performed using a Kruskal-Wallis test. A non-compartmental pharmacokinetic analysis will be performed on the intensive sampling data at Week 7 and the time course of TFV washout in the difference biological matrices will be reported based on the detected concentrations following drug cessation. The results of this randomized trial will define the target concentration thresholds of TFV in blood, urine and oral fluid that can distinguish between different levels of TDF adherence. Such adherence ‘benchmarks’ can be applied to real-time drug testing and novel point-of-care tests to identify individuals with poor PrEP or ART adherence. ClinicalTrials.gov Identifier NCT03012607 .